Both guidelines state and discuss ... organizations as they are considered first-line treatment measures. Disease Management of Atopic Dermatitis: An Updated Practice Parameter notes that lukewarm ...

Gender bias in cardiac treatment guidelines is putting women at risk because ... BSI-045B just wrapped up a single-arm, proof-of-concept phase IIa study in moderate to severe atopic dermatitis.

The study, out of the University of California, San Francisco (UCSF), and the University of California, Berkeley, discovered a significant correlation between high-sodium diets and developing atopic ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

ICP-332 is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders, including atopic dermatitis (AD), vitiligo, inflammatory ...

The following is a summary of “Comparative safety of oral Janus kinase inhibitors versus dupilumab in patients with atopic ...

Researchers assessed the prevalence of occupational allergic contact dermatitis and characterized common occupational allergens in a cohort of construction workers.

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitis ZORYVE, a next-generation topical phosphodiesterase-4 ...

Atopic dermatitis is increasing in prevalence and currently affects 15-30% of children in urban areas. Immune dysregulation and an impaired epidermal barrier are important factors in the ...

Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Paris: Sanofi and Regeneron has announced that the US Food and Drug Administration (FDA) has accepted for review the ...

Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.